ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 360 filers reported holding ROYALTY PHARMA PLC in Q4 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $8,638 | -8.6% | 327,566 | +5.2% | 0.01% | -8.3% |
| Q1 2024 | $9,455 | -13.8% | 311,315 | -20.2% | 0.01% | -20.0% |
| Q4 2023 | $10,963 | -5.6% | 390,282 | -8.8% | 0.02% | -11.8% |
| Q3 2023 | $11,615 | -22.3% | 427,979 | -11.9% | 0.02% | -10.5% |
| Q2 2023 | $14,940 | -17.5% | 486,007 | -3.4% | 0.02% | -20.8% |
| Q1 2023 | $18,119 | -7.9% | 502,887 | +1.0% | 0.02% | -11.1% |
| Q4 2022 | $19,683 | -99.9% | 498,042 | +0.8% | 0.03% | -6.9% |
| Q3 2022 | $19,858,000 | -8.8% | 494,235 | -4.6% | 0.03% | +3.6% |
| Q2 2022 | $21,770,000 | +41.8% | 517,851 | +31.4% | 0.03% | +75.0% |
| Q1 2022 | $15,350,000 | -0.5% | 394,001 | +1.8% | 0.02% | +6.7% |
| Q4 2021 | $15,426,000 | +8.7% | 387,110 | -1.4% | 0.02% | 0.0% |
| Q3 2021 | $14,191,000 | -7.2% | 392,681 | +5.3% | 0.02% | -6.2% |
| Q2 2021 | $15,284,000 | -5.7% | 372,877 | +0.4% | 0.02% | -11.1% |
| Q1 2021 | $16,205,000 | +137.2% | 371,500 | +172.2% | 0.02% | +125.0% |
| Q4 2020 | $6,832,000 | – | 136,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $244,378,000 | 79.54% |
| Vantage Consulting Group Inc | 7,862,542 | $284,152,000 | 60.85% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $96,878,000 | 60.36% |
| Indie Asset Partners, LLC | 701,323 | $25,346,000 | 20.53% |
| HARVARD MANAGEMENT CO INC | 7,142,856 | $258,143,000 | 15.13% |
| Bleichroeder LP | 1,115,980 | $40,332,000 | 6.55% |
| Overbrook Management Corp | 785,132 | $28,375,000 | 6.16% |
| Geo Capital Gestora de Recursos Ltd | 194,305 | $7,022,000 | 3.21% |
| Brown University | 621,759 | $22,470,000 | 3.05% |
| Graypoint LLC | 610,584 | $22,067,000 | 2.71% |